Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.
Kyle Wood, MD, provides insight on the types of hyperoxaluria, the importance of disease education, and who should be screened for the disease.
"I do think there's a big opportunity, if [telemedicine is] used correctly, to overcome some of these workforce shortages," says Chad Ellimoottil, MD, MS.
Casey Seideman, MD, discusses the gender pay gap in urology and the path forward to address the issue.
Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.
Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.
A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.
“We found that medications allegedly causing priapism and the litigation surrounding that is significant because it means that the patient-physician relationship was not well established,” says Ariana Matz, MD.
Robert J. Motzer, MD, discusses health-related quality of life analyses from the phase 3 CLEAR trial of frontline pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma.
The UroLift System is a noninvasive treatment for patients with BPH that relieves prostate obstruction by lifting and holding the prostate tissue that is blocking the urethra.
In this interview, Amy M. Pearlman, MD, also discusses how she uses social media at professional conferences.
Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.
“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.
David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.
In an interview conducted during the 2021 ASCO Annual Meeting, Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, shared his expertise on trends in the treatment of patients with genitourinary cancers.
“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.
In the phase 3 VISION trial, adding the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death.
Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy.
“The complete clinical response rate of 48% was somewhat surprising, although consistent with our assumptions in terms of the statistical design of the study,” says Matthew Galsky, MD.
Urologist Amy M. Pearlman, MD, discusses how she uses social platforms such as Twitter, Facebook, and Tiktok to entertain and inform.
Dr. Michael Devitt, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.
The study follows a successful phase 1b/2 study, data from which were presented at the 2021 ASCO Annual Meeting.
“It's important for any urologist to gain a broader exposure and awareness to the tools and techniques available to help improve efficiency in the operating room and reduce the amount of wasteful time in between cases,” says Niki N. Parikh, MD, MBA, MSBA.
Sivakumar was a researcher on a study presented at the 2021 ASCO Annual Meeting that assessed ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.
Robert A. Figlin, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.
Laura Bukavina, MD, MPH, and Justin Dubin, MD, also discuss their own usage of social media and share advice for medical professionals using social media.
Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.
Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.
Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.
“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.
